A recent court ruling in British Columbia, Canada that focused on the "material change" clause in homeowners insurance policies could have the potential to shed a spotlight on the incompatibility of such a position with new federal cannabis laws. According to the Globe and Mail, The decision of Vancouver Supreme Court Justice Margot Fleming in February 2019 could very well have far-reaching effects for all homeowners in Canada who grow even a single marijuana plant inside their home.

So far, 2019 is turning out to be a very good year for many marijuana stocks. But not for all of them. Tilray (NASDAQ:TLRY), for example, is performing much worse than most of its peers, with its share price slipping nearly 16% year to date. However, Tilray ranked as the top-performing Canadian marijuana stock of 2018. The company has tremendous opportunities for growth in the future. If you’re looking to buy Tilray while it’s down, though, here are five things you should know first.

Today we’ve dug up four Canadian marijuana stocks that may have been overlooked due to their low stock prices.

Yet, these four cannabis stocks have outperformed the market by a wide margin on average, gaining 168% YTD on higher price and volume momentum.

Price and volume momentum indicate bullishness, as increased share prices on higher volumes show heightened investor interest in a stock.

A week after legal pot stores began opening up in Toronto, city officials are warning they will take tough action against those who continue to operate illegally.

"We are starting an aggressive enforcement action [which will continue] for the foreseeable future," Mark Sraga, the director of investigation services for municipal licensing and standards, told CBC Toronto.

"Currently, our intelligence tells us we have 20 illegal cannabis stores open and operating in the city."

The first nine licensed cannabis stores in Ontario opened for business on April 1. There are two stores operating in Toronto — Yorkville-based Ameri, which opened Sunday; and The Hunny Pot, which started a week earlier.

Aurora Cannabis (TSX:ACB)(NYSE:ACB) has been my favourite cannabis play for quite some time now.

Not only does the name get less attention than front runner Canopy Growth with its eccentric CEO Bruce Linton, who’s seemingly always in the spotlight of the financial media, but Aurora has a number of catalysts that could propel the stock much higher than any of its peers in the space over the next year or so.

Let’s have a closer look at the three catalysts that I believe will allow Aurora to get a big boost over its pot peers in the years ahead.

Innovation is in Aurora’s veins

Is it just me or is Aurora out-innovating its peers?

Another pot shop quietly opens in Toronto with soft launch to avoid massive lines

In case you haven't been paying attention, big things are happening with the marijuana industry. Last year, more than a dozen unique milestones were made, with the biggest of all being Canada's legalization of recreational weed. In passing the Cannabis Act, Canada became the first industrialized country in the world to give the green light to adult-use consumption.

We've also seen sales estimates for the industry soar. The team of Arcview Market Research and BDS Analytics has called for 38% global growth in 2019 to $16.9 billion, with investment bank Cowen Group forecasting up to $75 billion in sales by 2030.

Two Canadian cannabis producers, Aurora Cannabis (TSX:ACB) and Aphria Inc. (TSX:APHA), have been awarded contracts by the German government to cultivate and distribute medical marijuana throughout the European country.

Both companies say the decision by Germany's Federal Institute for Drugs and Medical Devices is provisional and subject to a mandatory 10-day waiting period, which allows unsuccessful bidders to submit a challenge before the final contract is signed.

If finalized, the cannabis produced by both Aurora and Aphria will supply the German medical marijuana market, which is the largest in Europe according to a recent report by market research firm Brightfield Group.

There's no denying it: Marijuana stocks have been virtually unstoppable since the year began. Although pot stocks more or less tread water during the month of March, the Horizons Marijuana Life Sciences ETF, the very first tradable cannabis exchange-traded fund, and an ETF that currently contains about four dozen marijuana stocks of varied weightings, rose by 54% during the first quarter.

As more states make it legal to smoke marijuana, some government officials, researchers and others worry what that might mean for one of the country's biggest public health successes: curbing cigarette smoking.

Though there are notable differences in health research findings on tobacco and marijuana, the juxtaposition strikes some as jarring after generations of Americans have gotten the message that smoking endangers their health.

"We're trying to stop people from smoking all kinds of things. Why do you want to legalize marijuana?" a New York City councilman, Republican Peter Koo, asked at a recent city hearing about the state's potential legalization of so-called recreational pot use.